Device and method for delivery of a medicament

a delivery device and medicament technology, applied in the direction of drug compositions, tobacco, metabolic disorders, etc., can solve the problems of deterioration of medicaments, limited use of pulmonary delivery, and limited use of medicaments

Inactive Publication Date: 2016-09-01
PHILIP MORRIS PROD SA
View PDF6 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although DPIs were introduced in the 1970s, their use has been limited due to the overwhelming dominance of MDIs.
Nevertheless, methods for the administration of most medicaments have not significantly deviated from delivery via the traditional intravenous / intramuscular and oral routes to include pulmonary delivery via inhalation.
The use of pulmonary delivery has been limited mainly to the administration of medicaments for the treatment of asthma.
This micronization step can cause problems during manufacture.
For example, the heat produced during milling can cause degradation of the medicament.
Additionally, metal can rub off some mills and contaminate the medicament.
Furthermore, due to the small size of the particles, dry powder formulations tend to agglomerate, especially in the presence of moisture.
Agglomeration results in low flowability of the particles which diminishes the efficacy of the dry powder formulation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Device and method for delivery of a medicament
  • Device and method for delivery of a medicament
  • Device and method for delivery of a medicament

Examples

Experimental program
Comparison scheme
Effect test

experiment # 3

[0181]EXPERIMENT #3: Evaluation of Leading Acid Candidates Under Ambient Temperature

[0182]Objective:

[0183]The objective of this experiment was to assess which of the leading acid candidates selected from the experiment described above will deliver the greatest amount of nicotine under ambient conditions.

[0184]Experimental Design:

[0185]The current experiment was carried out as described in the previous experiment except that the glass chambers were not immersed in a heated water bath, but sampled at ambient temperature. Individual experiments were carried out using the selected acid candidates: 3-Methyl-2-oxovaleric acid, Pyruvic acid, 2-Oxovaleric acid, 4-Methyl-2-oxovaleric acid, 3-Methyl-2-oxobutanoic acid and 2-Oxooctanoic acid. For each experiment a different acid was placed in Chamber A as in the previous experiment with nicotine free base in Chamber B. A nicotine free base control experiment was also conducted as in the previous experiment.

[0186]Results:

[0187]The following tab...

experiment # 4

[0190]EXPERIMENT #4: Assessment of Leading Acid Candidates from the Previous 70° C. and Ambient Temperature Experiments (Experiment 2 and 3 Respectively) Utilizing the Prior Art Design for Aerosol Generation

[0191]Objective:

[0192]The objective of this experiment was to compare the prior art configuration to the sequential orientation of acid and base to determine which yields higher nicotine delivery. The two leading acid candidates which generated similar nicotine delivery at 70° C. and one acid candidate which delivered the highest amount of nicotine under ambient temperature (from Experiments #2-3) were tested under 70° C. and ambient conditions, respectively.

[0193]Experimental Design:

[0194]In this experiment, two identical rectangular glass chambers exactly like those used in Experiment #2 were employed. Chamber A contained 200 μL of the leading acid and chamber B contained 200 μL of nicotine free base. The two chambers were connected via a “Y” shaped glass connector which was th...

experiment # 5

[0199]EXPERIMENT #5: Effectiveness of a Sequential Arrangement of an Acid Reservoir and a Base Reservoir to Provide an Acid Over Base Environment in the Development of an Aerosol Plume with Sufficient Concentrations of Nicotine

[0200]Objective:

[0201]The objective of this experiment was to determine the influence of the arrangement of the acid and base reservoirs in sequence allowing the acid vapors to be lifted into the nicotine free base chamber and over the nicotine to generate a plume cloud with sufficient quantities of nicotine free base. Pyruvic acid was selected for use in this experiment.

[0202]Experimental Design:

[0203]The experimental design was the same as in Experiment #2. This experiment was divided into two parts, A and B. The first part, A, involved the assessment of the use of 200 pi, each of nicotine free base and pyruvic acid in separate chambers collected over 3 samples (20 puffs per sample). The second part of the experiment (part B) involved a comparison of the abo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The disclosure relates to a method of enhancing nicotine or other medicament concentrations in a gaseous carrier. The methods are adaptable to the delivery of nicotine or other medicaments for therapeutic effect in various diseases, in particular nicotine for tobacco product use cessation, substitution and / or harm reduction. The disclosure further relates various devices and device design principles for practicing these methods.

Description

[0001]This is a divisional application of U.S. patent application Ser. No. 12 / 054,883, filed Mar. 25, 2008, which claims priority of U.S. Provisional Patent Application No. 60 / 909,302 filed Mar. 30, 2007, the disclosures of which are incorporated herein by reference.TECHNICAL FIELD[0002]The invention relates to devices and methods for delivering a medicament to a user. More particularly, the invention relates to devices and methods for delivering an aerosol of a medicament to a user's lungs.BACKGROUND ART[0003]Pulmonary drug delivery systems have been used for decades to deliver medicaments for the treatment of respiratory disorders. The principle behind pulmonary drug delivery is aerosolization of drug compounds to be delivered to bronchioles and alveoli. Despite facing challenges like particle size optimization and degradation, a number of companies have developed technologies to deliver treatments for diabetes, migraine, osteoporosis and cancer.[0004]The available delivery system...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/465A61M15/00A24F47/00A61K9/00A61K9/16A24F40/10A24F40/40A24F42/10A24F42/20A24F42/60
CPCA61K31/465A61K9/007A61M15/009A24F47/002A61K9/1617A61K31/4439A61M11/041A61M15/06A61M15/0091A61M2205/071A61M2205/8206A61M11/047A24B15/167A61P1/04A61P11/06A61P25/00A61P25/16A61P25/28A61P25/34A61P3/04A61P43/00A61P9/00A61P9/06A61P9/10A24F42/10A24F40/40A24F40/10A24F42/20A24F42/60A24B15/16A24F40/42
Inventor ROSE, JED E.ROSE, SETH D.TURNER, JAMES EDWARDMURUGESAN, THANGARAJU
Owner PHILIP MORRIS PROD SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products